阿比特龙与恩扎卢胺不良事件:EudraVigilance数据库分析及III期注册研究荟萃分析
本研究利用EudraVigilance数据库分析2013年1月至2019年1月阿比特龙(ABI)和恩扎卢胺(ENZ)相关不良事件(AE),并对III期注册研究(AFFIRM、PREVAIL、COU-AA)进行荟萃分析。结果显示ABI报告13562例、ENZ报告40599例个体病例,两药超90%的AE为严重不良事件;老年患者(>85岁和65-85岁)相比年轻患者(<65岁)心脏、感染、代谢和呼吸系统疾病风险增加。注册研究中ABI最常见AE为肝胆疾病,ENZ为精神与血管疾病,但EV数据库中部分AE未在注册研究中报告。
要点
- ABI与ENZ报告的AE中超90%为严重不良事件。
- 老年患者(>85岁和65-85岁)使用ABI或ENZ时心脏、感染、代谢和呼吸系统疾病风险增加。
- 注册研究中ABI最常见AE为肝胆疾病,ENZ为精神与血管疾病,EV数据库还发现注册研究未报告的AE。
核心结论
- EudraVigilance数据库揭示了注册III期研究未报告的多种不良事件,且不同年龄组的不良事件谱存在差异,临床医生在使用ABI或ENZ治疗去势抵抗性前列腺癌时应考虑这些数据。
研究设计与样本
- 研究分析了EudraVigilance数据库2013年1月至2019年1月期间ABI和ENZ相关不良事件报告,并按类别、严重程度和年龄组记录。
- 同时对III期注册研究(AFFIRM、PREVAIL、COU-AA)报告的不良事件进行了荟萃分析。
主要发现
- EudraVigilance数据库中ABI相关个体病例为13562例,ENZ相关个体病例为40599例。
- 两种药物报告的AE中超过90%被定义为严重不良事件。
- 与年轻患者(<65岁)相比,使用ABI或ENZ的老年患者(>85岁和65-85岁)心脏、感染、代谢和呼吸系统疾病风险增加。
- 根据注册III期研究,ABI治疗患者最常见AE为肝胆疾病,ENZ治疗患者最常见AE为精神和血管疾病。
- EudraVigilance数据库中部分AE未在注册III期研究中报告。
临床怎么用
- 临床医生在使用ABI或ENZ治疗去势抵抗性前列腺癌时,应关注EudraVigilance数据库揭示的注册研究未报告的AE及年龄相关的AE谱差异。
局限性
- EudraVigilance数据库未提供正在接受治疗的患者数量信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data from clinical trials do not always provide adequate information to judge the impact of new treatments when used in a real-world setting. The aim of our study was to analyze adverse events (AEs) associated with enzalutamide (ENZ) and abiraterone (ABI) using real-life data from the EudraVigilance (EV) database. METHODS: The EV database is the system for managing and analyzing information on suspected adverse reactions to medicines, which have been authorized or are being studied in clinical trials in the European Economic Area. We recorded the number of AEs for ABI and ENZ per category and severity from January 2013 to January 2019. In addition, we recorded AEs per age group. A meta-analysis of AEs reported in registrational phase III studies (AFFIRM, PREVAIL, COU-AA) was performed. RESULTS: The number of individual cases identified in EV database was 13,562 for ABI and 40,599 for ENZ. Over 90% of the reported AEs were defined as serious for both drugs. Older patients (>85 years and 65-85 years) treated with ABI or ENZ are at increased risk of cardiac, infectious, metabolic, and respiratory disorders when compared with younger patients (<65). According to registrational phase III studies, the most frequent AEs in patients treated with ABI are hepatobiliary disorders, while the most frequent AEs in patients treated with ENZ are psychiatric and vascular disorders. Several AEs present in the EV database are not reported in the registrational phase III studies. It is important to note that we have no information on the number of patients under treatment in the EV database. CONCLUSIONS: The EV database highlights several AEs that are not reported in registrational phase III studies as well as different AEs profiles according to age. Clinicians should consider these data when treating patients with castration-resistant prostate cancer with ABI or ENZ.
引用
- De Nunzio C, Lombardo R, Tema G, et al. Adverse events related to abiraterone and enzalutamide treatment: analysis of the EudraVigilance database and meta-analysis of registrational phase III studies. Prostate Cancer Prostatic Dis. 2019. PMID: 31685981. doi:10.1038/s41391-019-0182-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。